HERSIMA 150mg Injection is a monoclonal antibody therapy containing Trastuzumab, specifically designed to target and treat HER2-positive breast and gastric cancers. HER2 (human epidermal growth factor receptor 2) is a protein that promotes cancer cell growth in certain types of cancer. HERSIMA works by binding to HER2 receptors on cancer cells, blocking their activity, and activating the immune system to attack and destroy these cells.

Key Features:

• Precisely targets HER2-positive cancer cells.
• Slows tumor growth and prevents disease progression.
• Can be utilized in mix with different treatments for improved viability.
• Administered as an intravenous infusion under medical supervision.

Indications:

HERSIMA 150mg Injection is used for the treatment of:

• HER2-positive breast cancer (early-stage and metastatic).
• HER2-positive gastric cancer or gastroesophageal junction cancer.

Dosage and Administration:

HERSIMA 150mg Injection is administered intravenously by a healthcare professional. The dosage and frequency are determined based on the patient’s weight, condition, and overall treatment plan.

Precautions:

• Patients should inform their doctor about any pre-existing heart conditions, infections, or previous treatments.
• Regular monitoring of heart function and overall health is essential during therapy.
• HERSIMA is not recommended during pregnancy as it may harm the fetus. Effective contraception is advised during treatment and for at least 7 months after the final dose.

Benefits:

HERSIMA 150mg Injection provides a targeted approach to managing HER2-positive cancers, improving survival rates, reducing tumor burden, and enhancing the quality of life for patients.

FAQs:

1. What is HERSIMA 150mg Injection used for?

HERSIMA 150mg Injection is used to treat HER2-positive breast cancer (early-stage and metastatic) and HER2-positive gastric or gastroesophageal junction cancer. It targets the HER2 protein to slow tumor growth, reduce disease progression, and improve survival rates.

2. How does HERSIMA 150mg Injection work?

HERSIMA contains Trastuzumab, a monoclonal antibody that binds to HER2 receptors on cancer cells. By blocking HER2 activity, it prevents cancer cell growth and activates the immune system to attack and destroy these cells.

3. How is HERSIMA 150mg Injection administered?

HERSIMA 150mg Injection is given as an intravenous infusion under the supervision of a healthcare professional. The dosage and frequency are tailored to the patient’s weight, condition, and treatment plan.

4. Can HERSIMA 150mg Injection be used with other treatments?

Yes, HERSIMA is often combined with chemotherapy, hormonal therapy, or other targeted therapies to enhance its effectiveness in treating HER2-positive cancers.

5. Is HERSIMA 150mg Injection safe during pregnancy?

HERSIMA is not recommended during pregnancy as it may harm the fetus. Women of childbearing age should use effective contraception during treatment and for at least 7 months after the final dose.

6. What precautions should I take before starting HERSIMA 150mg Injection?

• Inform your doctor about any heart conditions, infections, or previous cancer treatments.
• Regular monitoring of heart function and overall health is crucial during treatment.

7. Can HERSIMA 150mg Injection be self-administered?

No, HERSIMA must be administered by a healthcare professional in a clinical setting due to the need for precise dosage and monitoring for infusion reactions.